DK0458064T3 - Stabilisering af somatotropiner ved modificering af cysteinrester - Google Patents
Stabilisering af somatotropiner ved modificering af cysteinresterInfo
- Publication number
- DK0458064T3 DK0458064T3 DK91106224.8T DK91106224T DK0458064T3 DK 0458064 T3 DK0458064 T3 DK 0458064T3 DK 91106224 T DK91106224 T DK 91106224T DK 0458064 T3 DK0458064 T3 DK 0458064T3
- Authority
- DK
- Denmark
- Prior art keywords
- polypeptides
- proteins
- cysteine residues
- somatotropins
- stabilization
- Prior art date
Links
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 title abstract 2
- 230000006641 stabilisation Effects 0.000 title 1
- 238000011105 stabilization Methods 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 235000018102 proteins Nutrition 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000003839 Human Proteins Human genes 0.000 abstract 1
- 108090000144 Human Proteins Proteins 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51904790A | 1990-05-04 | 1990-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0458064T3 true DK0458064T3 (da) | 1998-04-27 |
Family
ID=24066559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK91106224.8T DK0458064T3 (da) | 1990-05-04 | 1991-04-18 | Stabilisering af somatotropiner ved modificering af cysteinrester |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0458064B1 (no) |
| JP (1) | JPH069696A (no) |
| KR (1) | KR100213455B1 (no) |
| AT (1) | ATE163431T1 (no) |
| AU (1) | AU639324B2 (no) |
| CA (1) | CA2041742A1 (no) |
| DE (1) | DE69128944T2 (no) |
| DK (1) | DK0458064T3 (no) |
| ES (1) | ES2113354T3 (no) |
| FI (1) | FI912144A (no) |
| GR (1) | GR3026436T3 (no) |
| IE (1) | IE911511A1 (no) |
| IL (1) | IL97932A (no) |
| NO (1) | NO911752L (no) |
| NZ (1) | NZ237959A (no) |
| PT (1) | PT97539B (no) |
| ZA (1) | ZA913359B (no) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| GB9100381D0 (en) * | 1991-01-09 | 1991-02-20 | Erba Carlo Spa | Human bfgf derivatives,their analogs and process for their production |
| WO1993000109A1 (en) * | 1991-06-28 | 1993-01-07 | Genentech, Inc. | Method of stimulating immune response using growth hormone |
| US5336488A (en) * | 1991-08-07 | 1994-08-09 | American Cyanamid Company | Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines |
| AU666914B2 (en) * | 1991-12-10 | 1996-02-29 | Tanox Biosystems, Inc. | Cytokines with an unpaired cysteine residue and conjugates thereof |
| WO1994012219A2 (en) * | 1992-11-25 | 1994-06-09 | Amgen Boulder Inc. | Modified insulin-like growth factors |
| EP0622394A1 (en) * | 1993-04-30 | 1994-11-02 | S.A. Laboratoires S.M.B. | Reversible modification of sulfur-containing molecules with polyalkylene glycol derivatives and their use |
| US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
| US7153943B2 (en) | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
| US7270809B2 (en) | 1997-07-14 | 2007-09-18 | Bolder Biotechnology, Inc. | Cysteine variants of alpha interferon-2 |
| DE69838552T2 (de) | 1997-07-14 | 2008-05-21 | Bolder Biotechnology, Inc., Louisville | Derivate des wachstumshormons und verwandte proteine |
| US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
| US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| AU2008202371B2 (en) * | 1999-01-14 | 2012-08-02 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| AU2001274853B2 (en) | 2000-05-16 | 2007-03-22 | Bolder Biotechnology, Inc. | Methods for refolding proteins containing free cysteine residues |
| JP2004524020A (ja) * | 2001-01-11 | 2004-08-12 | マキシゲン・エイピーエス | 改良された成長ホルモン分子 |
| OA13063A (en) * | 2001-11-20 | 2006-11-10 | Pharmacia Corp | Chemically-modified human growth hormone conjugates. |
| JP5207590B2 (ja) | 2002-12-26 | 2013-06-12 | マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド | 増強された生物学的能力を有するインターフェロン−βのポリマー結合体 |
| WO2005034988A1 (en) * | 2003-10-10 | 2005-04-21 | Novo Nordisk A/S | Long-acting molecules in sustained release formulations |
| US7524813B2 (en) | 2003-10-10 | 2009-04-28 | Novo Nordisk Health Care Ag | Selectively conjugated peptides and methods of making the same |
| WO2007041614A2 (en) | 2005-10-03 | 2007-04-12 | Bolder Biotechnology, Inc. | Long acting vegf inhibitors and methods of use |
| EP2102355B1 (en) | 2006-12-14 | 2016-03-02 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
| EP2525834B1 (en) * | 2010-01-22 | 2019-07-17 | Novo Nordisk Health Care AG | Growth hormones with prolonged in-vivo efficacy |
| JP6464145B2 (ja) | 2013-04-05 | 2019-02-06 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 成長ホルモン化合物製剤 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2514950B2 (ja) * | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質，その製造法および中間体 |
| US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
| DE68929273T2 (de) * | 1988-08-24 | 2001-07-05 | American Cyanamid Co., Wayne | Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung |
| US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
-
1991
- 1991-04-18 AT AT91106224T patent/ATE163431T1/de not_active IP Right Cessation
- 1991-04-18 DK DK91106224.8T patent/DK0458064T3/da active
- 1991-04-18 EP EP91106224A patent/EP0458064B1/en not_active Expired - Lifetime
- 1991-04-18 ES ES91106224T patent/ES2113354T3/es not_active Expired - Lifetime
- 1991-04-18 DE DE69128944T patent/DE69128944T2/de not_active Expired - Fee Related
- 1991-04-24 IL IL97932A patent/IL97932A/en not_active IP Right Cessation
- 1991-04-26 NZ NZ237959A patent/NZ237959A/en unknown
- 1991-04-29 AU AU76075/91A patent/AU639324B2/en not_active Ceased
- 1991-05-02 CA CA002041742A patent/CA2041742A1/en not_active Abandoned
- 1991-05-02 PT PT97539A patent/PT97539B/pt not_active IP Right Cessation
- 1991-05-02 JP JP3128190A patent/JPH069696A/ja active Pending
- 1991-05-03 FI FI912144A patent/FI912144A/fi not_active Application Discontinuation
- 1991-05-03 KR KR1019910007216A patent/KR100213455B1/ko not_active IP Right Cessation
- 1991-05-03 IE IE151191A patent/IE911511A1/en not_active Application Discontinuation
- 1991-05-03 ZA ZA913359A patent/ZA913359B/xx unknown
- 1991-05-03 NO NO91911752A patent/NO911752L/no unknown
-
1998
- 1998-03-24 GR GR970403459T patent/GR3026436T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2113354T3 (es) | 1998-05-01 |
| IE911511A1 (en) | 1991-11-06 |
| DE69128944T2 (de) | 1998-06-25 |
| DE69128944D1 (de) | 1998-04-02 |
| FI912144A (fi) | 1991-11-05 |
| EP0458064B1 (en) | 1998-02-25 |
| KR910020032A (ko) | 1991-12-19 |
| ATE163431T1 (de) | 1998-03-15 |
| AU639324B2 (en) | 1993-07-22 |
| IL97932A0 (en) | 1992-06-21 |
| IL97932A (en) | 1998-02-22 |
| PT97539A (pt) | 1992-02-28 |
| JPH069696A (ja) | 1994-01-18 |
| GR3026436T3 (en) | 1998-06-30 |
| PT97539B (pt) | 1998-08-31 |
| ZA913359B (en) | 1992-03-25 |
| NO911752D0 (no) | 1991-05-03 |
| NO911752L (no) | 1991-11-05 |
| NZ237959A (en) | 1994-05-26 |
| EP0458064A3 (en) | 1992-06-17 |
| CA2041742A1 (en) | 1991-11-05 |
| KR100213455B1 (ko) | 1999-08-02 |
| FI912144A0 (fi) | 1991-05-03 |
| EP0458064A2 (en) | 1991-11-27 |
| AU7607591A (en) | 1991-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0458064T3 (da) | Stabilisering af somatotropiner ved modificering af cysteinrester | |
| DK0469074T3 (da) | Cystein-tilsatte varianter af IL-3 og kemiske modifikationer deraf | |
| FI910286A0 (fi) | Analoger av humant insulin och preparat innehaollande dessa. | |
| AU4020289A (en) | Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis of chemical derivatization | |
| SE7705432L (sv) | Polypeptid och sett for dess framstellning | |
| DK97987D0 (da) | Solubilisering af proteiner til farmaceutiske sam mensaetninger under anvendelse af polymerkonjugation | |
| NO954342L (no) | Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav | |
| ATE121755T1 (de) | Deletionsanaloga von magaininpeptiden. | |
| DK491487A (da) | Dna-sekvens til ekspressionering af biologisk aktivt faktor xiii og anvendelse af samme | |
| NO932148L (no) | Fusjonspolypeptider | |
| DK0547064T3 (da) | Proteaseresistent PDGF og anvendelsesfremgangsmåde | |
| MX9203175A (es) | Composicion de implante que contiene un peptido, polipeptido o proteina biologicamente activa y procedimiento para su preparacion. | |
| DK0533408T3 (da) | Kosmetik og farmaceutika indeholdende extensiner | |
| ATE173739T1 (de) | Stabile zusammensetzung von polypeptiden | |
| SE8200757L (sv) | Biologiskt aktiva peptider | |
| DK5693D0 (da) | Kloning og fremstilling af polypeptidanaloger af humant fibronektins cellebindingsomraade, polypeptidanaloger af humant fibronektins cellebindingsomraade og anvendelse af saadanne polypeptidanaloger | |
| FR2592049A1 (fr) | Nouveaux analogues de composes polypeptidiques hypocalcemiants epargnant le calcium de l'organisme, leur preparation et les medicaments contenant ces principes actifs | |
| DE59008844D1 (de) | Benzylselenobenzamide von Aminopyridinen und Picolylaminen. | |
| ES2061809T3 (es) | Un metodo para preparar un derivado de calcitonina. | |
| NO873751L (no) | Lymfocytt-aktiverende polypeptider. | |
| ZA896437B (en) | Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis or chemical derivatization | |
| ATE90942T1 (de) | (3-diethylaminopropyl)-1-amino-5methyldipyrido(4,3-b>(3,4-f>indoltrihydrochlori . | |
| DK318086A (da) | Praeparat til behandling af haemofili a inhibitorpatienter samt fremgangsmaade til fremstilling af et saadant praeparat |